×
About 758 results

ALLMedicine™ Paroxysmal Supraventricular Tachycardia Center

Research & Reviews  148 results

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal...
https://doi.org/10.1161/CIRCEP.122.010915
Circulation. Arrhythmia and Electrophysiology; Stambler BS, Plat F et. al.

Nov 29th, 2022 - Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for...

Repair of Congenital Right Atrial Aneurysm Associated With Wolff-Parkinson-White Syndro...
https://doi.org/10.14503/THIJ-20-7388
Texas Heart Institute Journal; Movsesyan R, Termosesov S et. al.

Oct 13th, 2022 - This report describes our experience with a 5-year-old girl who had an extremely rare presentation of a right atrial aneurysm and associated Wolff-Parkinson-White syndrome. Before being referred to our department, she underwent an ineffective radi...

"Forced inspiratory suction and swallow tool" a novel instrument to convert paroxysmal ...
https://doi.org/10.1016/j.ajem.2022.09.002
The American Journal of Emergency Medicine; Mantha Y, Ebin J et. al.

Sep 19th, 2022 - Paroxysmal Supraventricular Tachycardia (SVT) is an arrhythmia with sudden onset and termination, characterized by a fast heart rate and a narrow QRS complex. There are several remedies that have been described to convert the SVT, such as the Vals...

Prognostic value of cardiac troponin in dialysis patients with paroxysmal supraventricu...
https://doi.org/10.1097/MD.0000000000030513
Medicine Wang CK, Yen CC et. al.

Sep 11th, 2022 - A rise in cardiac troponin I (cTnI) is common in supraventricular tachycardia (SVT). While troponin elevation in SVT is thought to be a predictor of future adverse events in patients with prior coronary artery disease, the prognostic significance ...

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
https://clinicaltrials.gov/ct2/show/NCT05410860

Aug 17th, 2022 - The study is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of PSVT in an at-home setting. This is an event-driven stud...

see more →

Drugs  112 results see all →

Clinicaltrials.gov  18 results

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
https://clinicaltrials.gov/ct2/show/NCT05410860

Aug 17th, 2022 - The study is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of PSVT in an at-home setting. This is an event-driven stud...

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
https://clinicaltrials.gov/ct2/show/NCT04072835

Jul 27th, 2022 - NODE-303 is a multi-center, open label (OL) study to evaluate the safety of etripamil NS in patients with PSVT. Patients will be provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS will be self-appli...

Modified Valsalva Maneuver: A Realist Evaluation
https://clinicaltrials.gov/ct2/show/NCT05466227

Jul 20th, 2022 - Cardiac arrhythmia, specifically paroxysmal supraventricular tachycardia (SVT), accounts for a substantial proportion of emergency medical services resources utilization. Restoring a normal sinus rhythm (reconversion) should be done quickly and ef...

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
https://clinicaltrials.gov/ct2/show/NCT04952610

Apr 4th, 2022 - Etripamil NS addresses an unmet medical need since there are currently no short-acting products available for patient self-administered treatment of episodes of PSVT. The only currently available acute pharmacological therapy is IV treatment with ...

A Real-world Study of Cardiac Ablation for PSVT Using ST Catheter
https://clinicaltrials.gov/ct2/show/NCT04923815

Feb 23rd, 2022 - Paroxysmal supraventricular tachycardia known as PSVT includes atrioventricular reentrant tachycardia (AVRT) and atrioventricular nodal reentrant tachycardia (AVNRT). This study is multicenter, retrospective, cohort study. This study will collect ...

see more →

News  17 results

RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT
https://www.medscape.com/viewarticle/982787

Oct 20th, 2022 - A nasal spray containing the investigational calcium channel blocker etripamil is efficacious and safe in patients with paroxysmal supraventricular tachycardia, topline results suggest. The RAPID trial met its primary endpoint demonstrating a "sta...

SPRINT BP Control Benefit Fizzles Out; Hot Flashes and CVD; Metformin for Afib?
https://www.medpagetoday.com/cardiology/prevention/101276

Oct 18th, 2022 - In a new policy statement, the American College of Cardiology endorsed more flexible hours and work arrangements so that cardiologists and trainees can have a better work-life balance. High-intensity care following heart failure (HF) hospitalizati...

Nasal Spray for Converting Paroxysmal SVT Seems Feasible, Safe for Long-term Use
https://www.medscape.com/viewarticle/973808

May 11th, 2022 - A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular tachycardia (PSVT), has advanced another step i...

Nasal spray resurrected after showing clinical benefits for PSVT
https://www.mdedge.com/cardiology/article/240181/heart-failure/nasal-spray-resurrected-after-showing-clinical-benefits-psvt
Ted Bosworth

May 16th, 2021 - Significant improvement in the control of symptoms related to paroxysmal supraventricular tachycardia (PSVT) is resurrecting etripamil as a self-administered nasal spray a year after it failed to meet the primary endpoint in a phase 3 trial, accor.

Nasal Spray Resurrected After Showing Clinical Benefits for PSVT
https://www.medscape.com/viewarticle/951243

May 16th, 2021 - Significant improvement in the control of symptoms related to paroxysmal supraventricular tachycardia (PSVT) is resurrecting etripamil as a self-administered nasal spray a year after it failed to meet the primary endpoint in a phase 3 trial, accor...

see more →

Patient Education  8 results see all →